NDAORALTABLET
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
XYZAL ALLERGY 24HR (levocetirizine dihydrochloride) by Sanofi is levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of h 1 receptors. First approved in 2017.
Drug data last refreshed 9h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XYZAL ALLERGY 24HR is an oral tablet containing levocetirizine dihydrochloride, the active S-enantiomer of cetirizine. It is a selective H1-receptor antagonist used to treat allergic rhinitis and urticaria. Levocetirizine demonstrates 2-fold higher H1-receptor affinity than racemic cetirizine, providing 24-hour symptom relief with once-daily dosing.
Peak
Product is at peak revenue stage with moderate competitive pressure (30), suggesting stable commercial team size and mature market positioning.
Mechanism of Action
Levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of H 1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients
Started Jun 2012
283 enrolled
Perennial Allergic Rhinitis
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin
Started Mar 2008
173 enrolled
Allergic RhinitisChronic Urticaria
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months
Started Mar 2008
69 enrolled
Allergic RhinitisChronic Urticaria
Worked on XYZAL ALLERGY 24HR at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.